����VR��Ƶ

����VR��Ƶ’s work has delivered world firsts for vaccines against many of its priority pathogens including the first licensed Chikungunya vaccine, the first ever Lassa fever and MERS vaccines to reach Phase II trials, the first Rift Valley fever vaccine to be studied in Phase II in an endemic region and vaccines against Nipah virus that are on the cusp of entering Phase II.

����VR��Ƶ has also supported programmes to generate data needed to expand access to Ebola, Mpox and Marburg vaccines.

����VR��Ƶ was among the first funders of COVID-19 vaccines, ultimately building one of the world’s largest portfolios, seven of which were licensed. The coalition also conceptualised and co-founded COVAX, which delivered nearly two billion doses of COVID-19 vaccines to 146 countries , saving an estimated 2.7 million lives in lower-income regions.

����VR��Ƶ is the world’s leading funder of R&D into broadly protective coronavirus vaccines, investing in 13 vaccine candidates designed to counter both known and emerging threats from the coronavirus family.

����VR��Ƶ’s network of Global South vaccine manufacturing partners on three continents is helping to boost sustainable vaccine production and outbreak response manufacturing capacity. Its global networks of preclinical facilities and laboratories are ready to respond rapidly to outbreaks close to their source.

����VR��Ƶ has leveraged its unique role as a coalition to galvanise support and drive progress on the 100 Days Mission—a life-saving pandemic preparedness plan that is today embedded into national health security strategies around the world.